尼妥珠单抗联合术后同步放化疗治疗华人恶性胶质瘤的Ⅰ期临床试验  

PhaseⅠStudy of nimotuzumab combined with postoperative chemoradiotherapy in Chinese patients with malignant glioma

作　　者：李文斌[1] 陈静[1] 赵艳杰[1] 康勋[1] 陈怡东[2] 邱晓光[3] 

机构地区：[1]首都医科大学附属北京世纪坛医院肿瘤中心,北京市100038 [2]首都医科大学附属北京世纪坛医院放疗科,北京市100038 [3]首都医科大学附属北京天坛医院放疗科

出　　处：《中国肿瘤临床》2013年第23期1455-1459,共5页Chinese Journal of Clinical Oncology

基　　金：国家高技术发展计划"863计划"项目(编号:2012AA02A508)资助~~

摘　　要：目的：恶性胶质瘤的预后较差，急需探索新的治疗策略以提高疗效。尼妥珠单抗是一种人源化抗表皮生长因子受体的单克隆抗体，能够抑制肿瘤细胞增殖，在一些恶性胶质瘤的Ⅰ/Ⅱ期临床研究中显示出了良好的耐受性及有效性。为此进行Ⅰ期临床试验，观察尼妥珠单抗联合术后同步放化疗治疗恶性胶质瘤的药物不良反应，耐受剂量及临床可行性。方法：选取经病理确诊的Ⅲ～Ⅳ级脑胶质瘤术后患者为研究对象，采用术后替莫唑胺同步放化疗的标准治疗方案加尼妥珠单抗靶向治疗。尼妥珠单抗分100、200、400 mg/周3个剂量级，每剂量组3～6例，从低剂量组开始用药，如3例均未出现3级以上不良反应则进入下一剂量组。尼妥珠单抗采用静脉滴注，放疗期间1次/周，共6次。结果：共有9例恶性胶质瘤入组，其中Ⅲ级胶质瘤7例，Ⅳ级2例。治疗过程中出现的不良反应均为1～2级，骨髓抑制为最常见的不良反应。临床治疗剂量达到400 mg/周时并未出现3级以上不良反应，可良好耐受。3个月后评价近期疗效，5例病情稳定，4例出现进展。结论：本研究显示尼妥珠单抗联合术后同步放化疗对于治疗华人恶性胶质瘤的不良反应轻微，可良好耐受。Objective：The poor prognosis of patients with malignant gliomas （MG） has led to the search for new therapeutic strat-egies. Recently, nimotuzumab has been studied as a new anti-EGFR-receptor humanized monoclonal antibody in patients with MG, who showed improvement of outcome and good tolerability. We conducted phase I of our study to determine the toxicity, tolerated dose, and clinical feasibility of nimotuzumab in combination with concurrent chemoradiotherapy for Chinese MG patients after surgical resection. Methods：Patients with pathologically proven grades 3 and 4 glioma were enrolled in the study. The protocol included infu-sions of nimotuzumab plus standard Stupp schedule （postoperative radiotherapy in a total dose of 60 Gy in combination with daily te-mozolomide）. Patients received 6 weekly infusions of nimotuzumab at three levels （100, 200, and 400 mg/week）. If none of the first three patients enrolled at a dose level experienced dose-limiting toxicity （DLT）, the dose was increased, as appropriate. If DLT was ob-served, another three patients were added to the dose level. Results：Nine patients with MG were enrolled, including 7 with grade 3 MG and 2 with glioblastoma. The treatment was well tolerated, and no evidence of grade 3 or 4 adverse events was detected, even at the highest level （400 mg/week）. Grade 1 or 2 myelosuppression was the most common toxicity. Three months after treatment, stable dis-ease occurred in 5 patients, whereas progression disease was observed in 4 patients. Conclusion：Nimotuzumab combined with concur-rent chemoradiotherapy was associated with mild toxicity in Chinese MG patients.

关 键 词：恶性胶质瘤 表皮生长因子受体 尼妥珠单抗 同步放化疗 

分 类 号：R739.4[医药卫生—肿瘤]